Company Information

  

Address: 3579 VALLEY CENTRE DRIVE  
City: SAN DIEGO 
State: CA 
Zip Code: 92130 
Telephone: 804-827-2524 

Description of Business

Primary SIC Code: 2836
(As filed with the SEC)  

We are a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics. Phage therapeutics use bacteriophages, a family of viruses, to kill pathogenic bacteria. Phages have powerful and highly selective mechanisms of action that permit them to target and kill specific bacteria. We believe that phages represent a promising means to treat bacterial infections, especially those that have developed resistance to current therapies, including the so-called multi-drug-resistant or "superbug" strains of bacteria. The extensive use of antibiotics since their discovery in the 1940s has resulted in drug resistance among many disease-causing bacteria. According to the U.S. Centers for Disease Control and Prevention, or CDC, resistance to antibiotics threatens to reverse many of the key medical advances of the last half-century.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-11.83NAN/E
03/2017-184.20NAN/E
12/2016-247.00NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.05Total Liab/Total Assets0.47
Net Inc/Total Assets-1.04Total Liab/Inv Cap0.61
Net Inc/Inv Cap-1.36Total Liab/Comm Equity0.02
Pretax Inc/Net Sales-74.59Interest Coverage RatioNA
Net Inc/Net Sales-72.45Curr Debt/Equity0.08
Cash Flow/Net Sales-40.73LTD/Equity0.25
SG&A/NetSales32.36Total Debt/Equity0.33
Asset Utilization   Liquidity  
Net Receivables Turnover3.47Quick Ratio1.78
Inventory TurnoverNACurrent Ratio1.78
Inventory Day SalesNANet Rec/Curr Assets0.00
Net Sales/Work Cap0.09Inv/Curr AssetsNA
Net Sales/PP&E0.24  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 0.03 0.03 0.02 0.03
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 2.78 1.90 1.54 1.78
Operating Income -9.69 -3.36 -11.86 -3.41
Interest Exp NA NA NA NA
Pretax Income -7.76 -3.25 -10.06 -2.38
Other Income 1.92 0.11 1.81 1.03
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -6.46 -3.25 -9.50 -2.38

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 8.96 2.20 5.71 3.97
Receivables - Total 0.00 0.02 0.03 0.02
Inventories - Total NA NA NA NA
Total Current Assets 9.24 2.56 6.36 4.56
Net Property, Plant & Equipment 0.91 0.98 1.07 1.15
Total Assets 15.11 14.30 18.20 26.04
Liabilities        
Accounts Payable 2.97 2.03 2.59 3.14
Debt in Current Liabilities 0.61 0.60 0.80 NA
Total Current Liabilities 3.71 2.88 3.58 3.15
Long-Term Debt 0.39 2.33 2.44 1.65
Total Liabilities 5.25 7.65 8.47 7.81
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 0.09 0.17 0.17 0.11
Retained Earnings -391.08 -384.61 -381.36 -371.86
Treasury Stock NA NA NA NA
Total Stockholders' Equity 9.86 6.65 9.72 18.23
Total Liabilities and Stockholders' Equity 15.11 14.30 18.20 26.04

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -2.93 -3.30 -1.48 -3.13
Net Cash Provided by Investing Activities -0.00 -0.01 -0.01 -0.03
Net Cash Provided by Financing Activities 9.69 -0.21 3.24 -0.02

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.66-1.11--
12/20130.08-64.58--
12/20140.4123.11--
12/20150.48-0.52--
12/20160.26-18.84-247.00
Growth Rates-20.90----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/172098911.31




Report Date : 10/9/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.